Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis

Summary

Phase 3b study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Nail Psoriasis

Timeline

Start

2021-05-13

Primary completion

2024-04-05

Completion

2025-01-30

Outcome

Met primary endpoint

registry NUMBER Placebo: 0.042 proportion of subjects NUMBER Tildrakizumab 100 mg: 0.255 proportion of subjects analysis (superiority test); Placebo vs Tildrakizumab 100 mg; p = 0.00311 NCT03897075 ↗

Drugs

Indications